Sultana A, Banu L, Hossain M, Azmin N, Nila N, Sinha S
Viruses. 2025; 17(2).
PMID: 40006937
PMC: 11860708.
DOI: 10.3390/v17020182.
Atatreh N, Mahgoub R, Ghattas M
J Enzyme Inhib Med Chem. 2025; 40(1):2460045.
PMID: 39912405
PMC: 11803818.
DOI: 10.1080/14756366.2025.2460045.
Jones C, Beitelshees M, Williams B, Hill A, Welch V, True J
PNAS Nexus. 2024; 3(12):pgae558.
PMID: 39703231
PMC: 11658415.
DOI: 10.1093/pnasnexus/pgae558.
Bastos R, de Aguiar C, Cruz J, Ramos R, Kimani N, de Souza J
Int J Mol Sci. 2024; 25(12).
PMID: 38928422
PMC: 11204165.
DOI: 10.3390/ijms25126715.
Yaghi R, Andrews C, Wylie D, Iverson B
ACS Chem Biol. 2024; 19(7):1474-1483.
PMID: 38865301
PMC: 11267570.
DOI: 10.1021/acschembio.4c00096.
Self-Replicating RNA Derived from the Genomes of Positive-Strand RNA Viruses.
Meyers G, Tews B
Methods Mol Biol. 2024; 2786:25-49.
PMID: 38814389
DOI: 10.1007/978-1-0716-3770-8_2.
Quantitative Assessment of Energetic Contributions of Residues in a SARS-CoV-2 Viral Enzyme/Nanobody Interface.
Kumar A, Vashisth H
J Chem Inf Model. 2024; 64(6):2068-2076.
PMID: 38460144
PMC: 10966652.
DOI: 10.1021/acs.jcim.3c01933.
The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.
Xiao S, Yuan Z, Huang Y
Int J Mol Sci. 2023; 24(24).
PMID: 38138990
PMC: 10742813.
DOI: 10.3390/ijms242417162.
Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins.
Alanzi A, Parvez M, Al-Dosari M
Future Virol. 2023; 18(7):421-438.
PMID: 38051986
PMC: 10241455.
DOI: 10.2217/fvl-2022-0184.
identification of deep-sea fungal alkaloids as potential inhibitors of SARS-CoV-2, Delta and Omicron spikes.
Alanzi A, Parvez M, Al-Dosari M
Future Virol. 2023; .
PMID: 37908844
PMC: 10615363.
DOI: 10.2217/fvl-2023-0102.
Endothelial Glycocalyx Injury in SARS-CoV-2 Infection: Molecular Mechanisms and Potential Targeted Therapy.
Lv B, Huang S, Huang H, Niu N, Liu J
Mediators Inflamm. 2023; 2023:6685251.
PMID: 37674786
PMC: 10480029.
DOI: 10.1155/2023/6685251.
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiX.
Hetmann M, Langner C, Durmaz V, Cespugli M, Kochl K, Krassnigg A
Sci Rep. 2023; 13(1):11783.
PMID: 37479788
PMC: 10362000.
DOI: 10.1038/s41598-023-39071-z.
Could a Non-Cellular Molecular Interactome in the Blood Circulation Influence Pathogens' Infectivity?.
Hardy E, Sarker H, Fernandez-Patron C
Cells. 2023; 12(13).
PMID: 37443732
PMC: 10341357.
DOI: 10.3390/cells12131699.
Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling.
Mandal N, Rath S
Chem Phys. 2023; 573:111995.
PMID: 37342284
PMC: 10265933.
DOI: 10.1016/j.chemphys.2023.111995.
Design of novel pyrimidine based remdesivir analogues with dual target specificity for SARS CoV-2: A computational approach.
Dinesh T, Malgija B, Ranjana Ponraj M, Muralakar P, Thathapudi J, Kandasamy R
Int J Biol Macromol. 2023; 242(Pt 1):124443.
PMID: 37148943
PMC: 10158044.
DOI: 10.1016/j.ijbiomac.2023.124443.
Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.
Akanchise T, Angelova A
Antioxidants (Basel). 2023; 12(2).
PMID: 36829952
PMC: 9952277.
DOI: 10.3390/antiox12020393.
Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection.
Behura A, Naik L, Patel S, Das M, Kumar A, Mishra A
Biochim Biophys Acta Mol Basis Dis. 2022; 1869(3):166634.
PMID: 36577469
PMC: 9790847.
DOI: 10.1016/j.bbadis.2022.166634.
A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites.
Islam M, Islam N, Alom M, Kabir M, Halim M
Immunobiology. 2022; 228(1):152302.
PMID: 36434912
PMC: 9663145.
DOI: 10.1016/j.imbio.2022.152302.
Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates.
Wang Q, Liu Z
Eur J Med Chem Rep. 2022; 1:100003.
PMID: 36304139
PMC: 8237387.
DOI: 10.1016/j.ejmcr.2021.100003.
A comprehensive review on disposition kinetics and dosage of oral administration of , an alternative herbal medicine, in co-treatment of coronavirus disease.
Songvut P, Suriyo T, Panomvana D, Rangkadilok N, Satayavivad J
Front Pharmacol. 2022; 13:952660.
PMID: 36059950
PMC: 9437296.
DOI: 10.3389/fphar.2022.952660.